Form 4: Rapport Therapeutics CDO Executes Stock Sale

Chief Development Officer Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics common stock.

Summary

• Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, sold 20,225 shares of common stock.
• The shares were sold at a weighted average price of $39.9923 per share.
• The transaction was executed on April 17, 2026, pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
• Following the sale, the reporting person retains beneficial ownership of 246,426 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a routine divestment by an executive.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating the transaction was planned in advance rather than based on immediate non-public information.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in future short-term performance, though this was a planned divestment.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales executed via 10b5-1 plans are standard practice for executives to manage personal liquidity and are generally viewed as neutral by the market as they are not reactive to specific company news.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives to avoid potential conflicts of interest regarding insider trading regulations.

Stakeholder Impact

• Minimal impact expected as the sale was executed through a pre-planned trading program.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Insider Trading, Form 4, Biotech, Equity Sale